Senior Vice President, Translational Medicine
Dr. Ginnie (Hsiu-Chiung) Yang joined Wave in 2023 as Senior Vice President, Translational Medicine. She is responsible for executing on Wave’s innovative target portfolio and leveraging Wave’s multimodal RNA medicines platform to deliver a broad suite of first- or best-in-class pipeline candidates designed to repair or restore endogenous proteins.
Ginnie joined Wave with 25 years of experience in drug discovery and translational medicine. She has worked extensively in metabolic, hepatic, central nervous system, cardiovascular, and autoimmune diseases using oligonucleotides, cell and gene therapies, peptides, antibodies, and small molecules as therapeutic modalities. She was previously at Bayer as Vice President of Therapeutic Area 2 in the Division of PreMed (Precision Medicine) Bayer Pharmaceutical Unit. There, she designed, executed, and led portfolio strategy for discovery of inflammation, exploratory pathobiology, and tissue repair targets. Prior to Bayer, she was at Novo Nordisk, AstraZeneca, and Eli Lilly where she led portfolio strategy and directed research and translational science teams focused on diabetes, obesity, NASH, and others. Her experience also includes leading significant clinical biomarker programs to deepen molecular understanding and elucidate disease drivers and patient stratification strategies in a variety of metabolic and cardiovascular diseases.
Ginnie received a PhD in Medical Biochemistry from The Ohio State University and completed post-doctoral research in Biochemistry and Molecular Biology at the University of California, San Diego. She earned her Bachelor of Science degree in Chemistry from National Taiwan Normal University.